Relevant bibliographies by topics / Cancer drug resistance, tumor metabolism / Books
To see the other types of publications on this topic, follow the link: Cancer drug resistance, tumor metabolism.

Books on the topic 'Cancer drug resistance, tumor metabolism'

Author: Grafiati
Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 25 books for your research on the topic 'Cancer drug resistance, tumor metabolism.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Dr, Mehta Kapil, and Siddik Zahid H, eds. Drug resistance in cancer cells. New York, NY: Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Benjamin, Bonavida, ed. Sensitization of cancer cells for chemo/immuno/radio-therapy. Totowa, NJ: Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

S, El-Deiry Wafik, ed. Tumor progression and therapeutic resistance. New York, NY: New York Academy of Sciences, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

B, Roninson Igor, ed. Molecular and cellular biology of multidrug resistance in tumor cells. New York: Plenum Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lauricella, Marianna, and Sonia Emanuele. Novel apoptotic drugs in targeting tumor cells. Trivandrum, Kerala, India: Researh Signpost, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kim, Kŏn-hong. Yubangam ŭi taje yangmul naesŏng saengchʻe chipʻyo palgul mit kŭ yuyongsŏng kŏmjŭng =: Identification of biomarkers for multidrug resistance and validation of markers in breast cancer tissue. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bonavida, Benjamin. Chemo-immunosensitization of resistant tumor cells to cell death by apoptosis, 2006. Trivandrum: Transworld Research Network, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Julia, Gee, Nicholson Robert I, and SpringerLink (Online service), eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Dordrecht: Springer Netherlands, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1940-, Tabuchi K., ed. Biological aspects of brain tumors: Proceedings of the 8th Nikko Brain Tumor Conference, Karatsu (Saga) 1990. Tokyo: Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gregory, Bock, Goode Jamie, Novartis Foundation, and Symposium on Mechanisms of Drug Resistance in Epilepsy : Lessons from Oncology (2001 : London, England), eds. Mechanisms of drug resistance in epilepsy: Lessons from oncology. Chichester, England: Wiley, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Bates, Susan E., Kapil Mehta, and Zahid H. Siddik. Drug Resistance in Cancer Cells. Springer, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Bonavida, Benjamin. Sensitization of Cancer Cells for Chemo/Immuno/Radio-Therapy. Humana Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Molecular Mechanisms Of Tumor Cell Resistance To Chemotherapy Targeted Therapies To Reverse Resistance. Springer-Verlag New York Inc., 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Gonzalez-Perez, Ruben R., and Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Gonzalez-Perez, Ruben R., and Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Gonzalez-Perez, Ruben R. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Gonzalez-Perez, Ruben R., and Bo R. Rueda. Tumor Angiogenesis Regulators. Taylor & Francis Group, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Pacak, Karel, and INTERNATIONAL SYMPOSIUM ON CATECHOLAMINE. Tumor Progression and Therapeutic Resistance (TPR) (Annals of the New York Academy of Sciences). New York Academy of Sciences, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Hiscox, Stephen, Julia Gee, and Robert I. Nicholson. Therapeutic Resistance to Anti-hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Hiscox Stephen Gee Julia Nicholson Robert I, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Biological aspects of brain tumors: Proceedings of the 8th Nikko Brain Tumor Conference, Karatsu (Saga) 1990. Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Multidrug resistance in cancer cells: Molecular, biochemical, physiological, and biological aspects. Chichester: J. Wiley, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

(Editor), Sudhir Gupta, and Takashi Tsuruo (Editor), eds. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects. Wiley, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Tsuruo, Takashi, and Sudhir Gupta. Multidrug Resistance in Cancer Cells: Molecular, Biochemical, Physiological and Biological Aspects. Wiley & Sons, Incorporated, John, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Full text
Abstract:
The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.
APA, Harvard, Vancouver, ISO, and other styles
25

Josephs, Debra H., Heather J. Bax, Giulia Pellizzari, James F. Spicer, Ana Montes, and Sophia N. Karagiannis. Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0001.

Full text
Abstract:
Despite improvements over the past decade in the treatment of ovarian cancer, many patients are at risk of recurrent disease and emerging drug resistance. The increased selectivity and reduced toxicity of molecularly targeted anti-cancer agents renders them attractive for development in ovarian cancer, and monoclonal antibodies targeting ovarian cancer-specific tumor antigens represent the largest such group investigated in this clinical setting. This chapter describes examples of monoclonal antibodies clinically evaluated for efficacy in ovarian cancer. These agents recognize molecular targets expressed on tumors or within tumor microenvironments that may be essential for tumor cell survival and proliferation. Recently, antibodies targeting checkpoint molecules on immune cells have shown efficacy in modulating anti-tumor immunity, and applications in ovarian carcinomas are evaluated. The chapter focuses on therapeutic agents’ attributes on targeting key cancer growth and progression pathways, and propensity to engender effector functions by activating immune effector cells in tumors and the circulation.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Cancer drug resistance, tumor metabolism' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography